Search Within

Ping Zhou

Formats
  1. Meeting Abstract (28)
  2. Journal Article (10)
  3. Book Section (5)
  4. Conference Paper (2)
Groups
  1. Department of Medicine (34)
  2. Hematologic Malignancies, Division of (33)
  3. Center for Hematologic Malignancies (22)
  4. Myeloma (13)
  5. Bone Marrow Transplant (9)
  6. Adult Leukemia (8)

More Groups

People
  1. Raymond Comenzo (45)
  2. Martin Fleisher (30)
  3. Julie Feldstein (26)
  4. Stephen Nimer (20)
  5. Daniel Filippa (13)
  6. Hani Hassoun (13)

More People

Years
  1. 2009 (1)
  2. 2008 (8)
  3. 2007 (4)
  4. 2006 (12)
  5. 2005 (8)
  6. 2004 (5)

More Years

Publications
  1. Blood (22)
  2. Amyloid (7)
  3. XIth International Symposium on Amyloidosis (5)
  4. British Journal of Haematology (3)
  5. Amyloid and Amyloidosis (2)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Taylor & Francis Group (7)
  3. CRC Press/Taylor & Francis Group (5)
  4. John Wiley & Sons (3)
  5. CRC Press (2)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk-adapted melphalan (MEL) with stem cell transplant (SCT) and adjuvant dexamethasone (D)+/- thalidomide (T) for AL patients achieves low treatment-related mortality (TRM) and high hematologic response rates
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Clark, B.; Stubblefield, M.; Fleisher, M.; Nimer, S. D.; more...
    Amyloid (2006)

    Fulltext@MSK | Save
  • Accuracy of the abdominal fat pad aspirate and ancillary test results in a patient population with a high prevalence rate of amyloidosis
    Meeting Abstract

    Clark, B.; Lin, O.; Moreira, A.; Teruya-Feldstein, J.; Antonescu, C.; Hassoun, H.; Zhou, P.; Fleisher, M.; Comenzo, R.
    Amyloid (2006)

    Fulltext@MSK | Save
  • CD32B on clonal plasma cells in systemic light-chain amyloidosis (AL) and multiple myeloma (MM): A target for immunotherapy in both disorders and a prognostic marker in MM
    Meeting Abstract

    Boruchov, A.; Zhou, P.; Olshen, A.; Rankin, C.; Bonvini, E.; Koenig, S.; Fleisher, M.; Rose, R.; McKenzie, S.; Maslak, P.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Pyridone 6, a Pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells
    Journal Article

    Pedranzini, L.; Dechow, T.; Berishaj, M.; Comenzo, R.; Zhou, P.; Azare, J.; Bornmann, W.; Bromberg, J.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: Patients can have both monoclonal gammopathies and hereditary amyloid proteins
    Journal Article

    Comenzo, R. L.; Zhou, P.; Fleisher, M.; Clark, B.; Teruya-Feldstein, J.
    Blood (2006)

    Fulltext@MSK | Save
  • Plasma cell gene-expression profiles in patients with systemic AL amyloidosis: Responses to melphalan and stem cell transplant are associated with differential expression of genes involved in translation, protein degradation and detoxification
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Wang, L. M.; Nimer, S. D.; Olshen, A. B.
    Blood (2005)

    Fulltext@MSK | Save
  • Seeking diagnostic confidence in typing amyloidosis: Prospective results with an algorithm to minimize misdiagnosis of immunoglobulin light-chain (AL) amyloidosis
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Wang, L. M.; Clark, B. D.; Fleisher, M.; Teruya-Feldstein, J.
    Blood (2005)

    Fulltext@MSK | Save
  • Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Adjuvant dexamethasone (D)+/- thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL)
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Nimer, S. D.; Comenzo, R. L.
    Blood (2005)

    Fulltext@MSK | Save
  • Interim analysis of a phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL)
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Comenzo, R. L.
    Biology of Blood and Marrow Transplantation (2005)

    Fulltext@MSK | Save